Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation
Galmed Pharmaceuticals rebrands to EoCene, changes ticker to EOCN. The company terminated its SEPA with Yorkville, raising $7.3M. EoCene focuses on GI diseases and cancers, integrating Colospan's medical device tech. It regained Nasdaq compliance and has $11.4M in cash. Changes take effect September 10, 2026.
How this was made
The 30-second read
Why it matters
The ticker change requires portfolio updates but does not alter the company's fundamentals; the SEPA termination reduces potential equity financing.
Market read
Primary relevance is administrative; modest short‑term price movement possible as investors adjust holdings to the new ticker.
What to watch
Termination of the $20 M SEPA line reduces future financing flexibility, which may affect long‑term growth.
Background
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced a corporate rebranding to EoCene Ltd., a new ticker EOCN, and the termination of its Standby Equity Purchase Agreement with Yorkville.
Market effects
Highlights growing convergence of medtech and biopharma in GI space, may spur interest in similar hybrid companies.
Israel‑based biotech visibility increases; Nasdaq listing remains unchanged.
Limited to investors tracking Nasdaq small‑cap biotech/medtech names.
Counterpoint
The rebrand could be a distraction; underlying cash position remains modest, limiting upside.
Key entities
- companyGalmed Pharmaceuticals Ltd.
Clinical‑stage biopharma rebranding to EoCene
- investorYorkville (YA II PN, LTD.)
Counterparty to the terminated SEPA
